Rubicon Research Limited announced the successful completion of a United States Food and Drug Administration (USFDA) inspection at its R&D facility in Canada through an official regulatory disclosure dated April 24, 2026. The pharmaceutical company communicated this development to both BSE Limited and National Stock Exchange of India Limited under SEBI regulations.

USFDA Inspection Details

The USFDA conducted an unannounced inspection at Rubicon Research's R&D facility located in Concord, Ontario, Canada. The inspection was completed over a four-day period from April 20, 2026 to April 24, 2026, providing regulatory authorities with comprehensive oversight of the company's research and development operations.

Regulatory Compliance Achievement

The inspection concluded without any Form-483 being issued, representing a significant positive outcome for the company. A Form-483 typically lists observations of conditions or practices that may constitute violations of FDA regulations, so its absence indicates the facility met regulatory standards during the inspection period.

Official Communication Structure

The disclosure was formally communicated to stock exchanges through a letter signed by Company Secretary Deepashree Omkar Tanksale with digital signature authentication. The communication was addressed to the Listing Departments of both BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street and National Stock Exchange of India Limited at Exchange Plaza, Bandra Kurla Complex.

Regulatory Framework

The company made this disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation requires listed companies to inform stock exchanges about material events that could impact investor decisions or share prices, ensuring transparency in corporate communications. The company emphasized its commitment to maintaining the highest standards of compliance and quality across its operations.

Rubicon Research Limited has received an Income Tax Assessment Order for Assessment Year 2023-24 from the Income Tax Department, Mumbai. The order was received on 21st April 2026 at 04:03 PM IST, and the company disclosed the matter on 22nd April 2026 through a regulatory filing under Regulation 30 of SEBI Listing Regulations.

Assessment Order Details

The assessment order was issued under section 143(3) read with sections 144C(3), 144B, and a demand notice under section 156 of the Income-tax Act, 1961. The order pertains to certain additions and disallowances related to Arms' Length Pricing adjustments to international transactions.

Financial Impact and Penalty Proceedings

The total additions and disallowances amount to Rs. 20,68,44,914. Consequently, the Income Tax Department has raised a total demand of Rs. 17,25,17,210, which is subject to the outcome of any appeal or rectification proceedings.

Along with the assessment order, a show cause notice has been issued for the initiation of penalty proceedings under section 270A of the Income-tax Act, 1961.

Company's Response and Legal Action

Rubicon Research Limited is currently in the process of filing an appeal before the appropriate appellate authority. Based on advice received from its tax advisors, the company believes its position is strong and remains confident of the merits of the case.

The company has complied with regulatory requirements by filing the disclosure under Regulation 30(6) and 30(13) of SEBI Listing Regulations, confirming that the information provided is true, correct and complete to the best of their knowledge and belief.